Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Sermorelin: Evidence Summary
Evidence summary for Sermorelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Sermorelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| GH stimulation testing | Tier A | 5 | Validated diagnostic tool for GH deficiency assessment |
| GH deficiency | Tier B | 12 | Well-established GH secretagogue with Phase III data; FDA-approved 1997-2008 for pediatric GHD |
| Anti-aging | Tier C | 4 | Limited controlled data for anti-aging indications; IGF-1 increases observed but outcomes unproven |
References (4)
- Phase 3 trial of sermorelin for pediatric growth hormone deficiency — Various . Journal of Clinical Endocrinology & Metabolism (1997)
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency . BioDrugs (1999) PMID: 18031173
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy — Geref International Study Group . Journal of Clinical Endocrinology & Metabolism (1996) PMID: 8772599
- Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency . Journal of Clinical Endocrinology & Metabolism (2013) PMID: 23559086